Tectonic Therapeutic initiated with a Neutral at UBS

Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights • Reported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adu

Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) • U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investig

Tectonic Therapeutic (TECX) reported Q2 results, highlighting progress in two clinical trials, TX45 for pulmonary hypertension and TX2100 for a rare bleeding disorder. The company has sufficient cash to fund operations into 2029. Net loss widened to $22.3M from $20M a year earlier. Hedge fund ownership increased, while short interest remains high at 17.86% of the float.

Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights • Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-

Tectonic Therapeutic (NASDAQ: TECX) said it completed enrollment in its 24-week APEX Phase 2 trial of TX45 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The trial enrolled 191 patients in 14 countries, with ~72% in CpcPH patients (PVR >3 WU). Topline results are expected in early Q1 2027.

Capricor (CAPR) stock rose after-hours as the company reaffirmed confidence in its Deramiocel treatment ahead of a November 22 decision. The HOPE-3 trial met its primary endpoint, showing a 1.1-point improvement in upper limb function. Capricor reported a Q3 net loss of $42.7 million and $198.5 million in cash reserves. Retail sentiment on StockTwits was extremely bullish, with mixed opinions on approval odds. CAPR stock is down 69% year-to-date.